PDG42 Reimbursement Program "Affordable Medicines” in Ukraine: Issues and Challenges

Zaliska, O.; Huz, V.; Maksymovych, N.

doi:10.1016/j.jval.2020.08.725

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to improve the quality of life of patients with chronic diseases, such as DM, due to the increase in the physical availability and economic affordability of drugs, a reimbursement system, which included only insulin drugs, was introduced in Ukraine in 2016. The next stage of increasing the availability of drugs was the implementation of the "Affordable Medicines" program in 2017, which provided patients with T2D with oral GLDs (Zaliska et al 2020).…”

Section: Introductionmentioning

confidence: 99%

Study of the influence of armed conflict on the reimbursement of oral glucose lowering drugs in Ukraine

Vlasenko¹,

Давтян²

2023

PHAR

View full text Add to dashboard Cite

The humanitarian crisis significantly affects the provision of medical and pharmaceutical care to PWD, and makes it difficult to predict its availability and affordability. It was established that despite the military actions in Ukraine, the reimbursement system is experiencing both negative and positive trends. Negative trends are : an increase in drug prices, the amount of patient co-payments, and a decrease in the number of glucose-lowering drugs that are subject to full reimbursement. Positive trends are: an increase in the amount of reimbursement and the number of glucose-lowering drugs that are included in the system reimbursements, including at the expense of extended dosage forms. The analysis showed that the war led to the introduction of positive changes – to increase the number of glucose-lowering drugs that are subject to full compensation.

show abstract

Section: Introductionmentioning

confidence: 99%

Study of the influence of armed conflict on the reimbursement of oral glucose lowering drugs in Ukraine

Vlasenko¹,

Давтян²

2023

PHAR

View full text Add to dashboard Cite

show abstract

“…При забезпеченні пацієнтів аптечний працівник має надати фармацевтичну допомогу, а саме інформувати пацієнта, які препарати, що підлягають повному відшкодуванню, наявні в аптеці, а на які встановлено доплату. Це допоможе зменшити фінансове навантаження на пацієнтів та збільшіть доступність ЦЗП, що є однією зі задач реімбурсації [30]. Одночасно надати вибір пацієнту, якщо він має пріоритети при виборі ЛЗ [20].…”

unclassified

Analysis of oral hypoglycemic drugs that are subject to reimbursement in Ukraine

Vlasenko

2022

Farm Zh

View full text Add to dashboard Cite

Increasing the affordability of pharmaceutical provision to the population is the most important task of the governments, especially in the context of health care reform. Therefore, considering that reimbursement of the cost of drugs increases their affordability, it is relevant to analyze the updated list of GLDs that are subject to reimbursement. The purpose of the work is to conduct an audit of oral GLDs for the treatment of type 2 diabetes, which are subject to reimbursement under the state program in Ukraine, and to study their affordability. The objects of the research were the State Register of Medicinal Products, the Register of Maximum Wholesale and Retail Prices for Drugs, which are subject to reimbursement under the program of state guarantees of medical care for the population. Bibliosemantic, marketing, analytical, graphical, generalizing analyzes and mathematical calculations were used. An audit was conducted of GLDs, except of insulin, for the treatment of patients with type 2 diabetes, the cost of which is subject to reimbursement under the program under the state guarantee program. Only three drugs under the INN are subject to reimbursement: metformin, glibenclamide, and gliclazide. The number of TNs is 51 Ukrainian-made and foreign-made GLDs, and the majority (76.9%) are domestic products. Metformin, gliclazide, and glibenclamide tablets are available in a sufficient assortment of 40 TN, 8 TN, and 3 TN tablets, respectively, in different dosages and packaging (No 30, No 60, No 90, No 120). There are no prolonged forms of metformin, although they are available on the pharmaceutical market of Ukraine. 3 glibenclamide drugs, 1 drug out of 8 – gliclazide, and 13 out of 40 drugs – metformin are subject to full reimbursement. Others require co-payments from the patient. Calculations of co-payments DDD of GLDs that are partially reimbursable, taking into account dosage and packaging, have been carried out. The co-payments for DDD ranges from UAH 0.111 to UAH 2.510 for gliclazide, and from UAH 0.105 to UAH 1.576 for metformin. The co-payments for foreign-made drugs is more than that of the domestic one. To increase the affordability of GLDs and the introduction of modern treatment schemes, it is necessary to expand the list of reimbursable GLDs, including prolonged forms of metformin and innovative drugs. Innovative drugs such as GLP1 and SGLT2 are recommended to be used at the beginning of treatment to prevent the development of DM complications.

show abstract

Impact of reimbursement program “Аffordable Medicines” on consumptiom of beta-blockers in Ukraine in 2017-2020

Gonchar

Sholoiko

2022

USMYJ

View full text Add to dashboard Cite

the article presents the results of the study of impact of the reimbursement program “Affordable medicines” on consumption of beta-blockers in Ukraine, used for treatment of cardiovascular diseases. Analysis was conducted based on analytical data of Ukrainian pharmaceutical market research system “PharmXplorer” of the company “Proxima Research”, with current legislation taken into account. It was estimated, that in 2021, according to international non-proprietary name and 5th level of ATC classification - two non-selective beta-blockers: propanolol (ATC code С07АА05) and sotalol (С07АА07); six selective beta-blockers: metoprolol (С07АВ02), atenolol (С07АВ03), betaxolol (С07АВ05), bisoprolol (С07АВ07), esmolol (С07АВ09) and nebivolol (С07АВ12); and one beta-blocker from alpha and beta blocking agents group – carvedilol (C07GA02) are allowed for medical use in Ukraine. From the beginning, when reimbursement program “Affordable medicines” was implemented (April 1st, 2017), only 4 beta-blockers were included in the reimbursement list. Consumption patterns were analyzed in terms of defined daily dose, and it was estimated that bisoprolol was the leader among all beta-blockers in terms of consumption in period from 2016 to 2020. The findings show, that among beta-blockers, that were included in the reimbursement list, the major annual growth of consumption was detected for bisoprolol and carvedilol, although the growth of consumption of metoprolol and atenolol was noted only within the first year of functioning of the reimbursement program “Affordable medicines”, and beginning from 2018, the consumption of these two beta-blockers was declining annually. Among beta-blockers, that were not included in the reimbursement list, the increase in annual growth of consumption was spotted for nebivolol and sotalol. DDD/1000 inhabitants/day indicators were calculated for each beta-blocker. It was found, that throughout the years the biggest value of this indicator was for bisoprolol – 8,46 in 2016; 11,74 in 2017; 15,28 in 2018 ; 16,88 and 17,48 in 2019 and in 2020 respectfully. The growth of this indicator can give evidence about positive effect of the reimbursement program “Affordable medicines” on consumption of bisoprolol and its affordability for population in Ukraine in 2017-2020.

show abstract

PDG42 Reimbursement Program "Affordable Medicines” in Ukraine: Issues and Challenges

Cited by 3 publications

References 0 publications

Study of the influence of armed conflict on the reimbursement of oral glucose lowering drugs in Ukraine

Study of the influence of armed conflict on the reimbursement of oral glucose lowering drugs in Ukraine

Analysis of oral hypoglycemic drugs that are subject to reimbursement in Ukraine

Impact of reimbursement program “Аffordable Medicines” on consumptiom of beta-blockers in Ukraine in 2017-2020

Contact Info

Product

Resources

About

PDG42 Reimbursement Program "Affordable Medicines” in Ukraine: Issues and Challenges

Cited by 3 publications

References 0 publications

﻿Study of the influence of armed conflict on the reimbursement of oral glucose lowering drugs in Ukraine

﻿Study of the influence of armed conflict on the reimbursement of oral glucose lowering drugs in Ukraine

Analysis of oral hypoglycemic drugs that are subject to reimbursement in Ukraine

Impact of reimbursement program “Аffordable Medicines” on consumptiom of beta-blockers in Ukraine in 2017-2020

Contact Info

Product

Resources

About

Study of the influence of armed conflict on the reimbursement of oral glucose lowering drugs in Ukraine

Study of the influence of armed conflict on the reimbursement of oral glucose lowering drugs in Ukraine